BioLife Plasma Services
The Analytical Development Synthetic Molecules Characterization Scientist leads scientific and technical work within Analytical Development, focusing on the characterization of synthetic molecules like peptides and PROTACs. This role supports the transition of novel compounds from Discovery into Development and first-in-human clinical studies while contributing to ongoing research across the development lifecycle. The position involves driving physicochemical profiling, solid-state screening, and analytical method development for Drug Substance and Drug Product.
Headquarters
Bannockburn, Illinois, United States
Company Size
5001-10000 employees
BioLife Plasma Services operates a network of plasma collection centers that collect donated human plasma used to manufacture life‑saving plasma‑derived therapies. The company focuses on donor safety and convenience, offering screening, regulated collection procedures, appointment scheduling, and compensation/rewards to encourage repeat donations. BioLife partners with biopharmaceutical manufacturers and maintains rigorous quality and regulatory standards to supply plasma for treatments such as immune deficiencies, bleeding disorders, and other therapeutic uses.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for BioLife Plasma Services.
Director, Synthetic Molecules Analytical R&D
AbbVie
Scientist I - Early Analytical Development, Synthetic Molecules
AbbVie
Senior Scientist I - Early Analytical Development, Synthetic Molecules
AbbVie
Senior Scientist I/II - Early Analytical Development, Synthetic Molecules
AbbVie
Scientist I - Early Analytical Development, Synthetic Molecules
AbbVie
Senior Scientist I/II - Early Analytical Development, Synthetic Molecules
AbbVie